[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2009″ holder_padding=”13px”]

Venous thromboembolism in the hematologic malignancies.

Falanga A, Marchetti M.

J Clin Oncol. 2009;27(29):4848-57.

Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

Imberti D, Di Nisio M, Donati MB, Falanga A, Ghirarduzzi A, Guarneri D, Piovella F, Santoro RC, Baldini E, Zampogna S; Italian Society for Thrombosis and Haemostasis.

Thromb Res. 2009;124(5):e32-40.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.

J Clin Oncol. 2009;27(29):4919-26.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2009;20 Suppl 4:182-4

Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.

Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A.

Haematologica. 2009;94(7):911-8.

Thrombosis associated with angiogenesis inhibitors.

Elice F, Rodeghiero F, Falanga A, Rickles FR.

Best Pract Res Clin Haematol. 2009;22(1):115-28.

Procoagulant mechanisms in tumour cells.

Falanga A, Panova-Noeva M, Russo L.

Best Pract Res Clin Haematol. 2009;22(1):49-60.